Onglyza (Saxagliptin) Legal Action Due to Onglyza (Saxagliptin) Dangers
Many patients are finding they are suffering serious side effects after taking Onglyza. Some of the more common side effects include runny or stuffy nose, sore throat, cough, headache or stomach pain. Onglyza can lead to low blood sugar, with symptoms such as sweating, extreme hunger, fast heartbeat, shaking, blurred vision, dizziness, or tingling of the hands and feet. The primary symptom of pancreatitis is severe stomach or abdominal pain which spreads to the back, sometimes accompanied by nausea and vomiting. Other potential side effects of Onglyza include vision disturbances, swelling in the hands, feet or ankles and easy bruising or bleeding.
Other DPP-4 Inhibitors Which Work Like Onglyza (Saxagliptin)
There are other drugs similar to Onglyza (Saxagliptin) which are also DPP-4 inhibitors (Gliptins). Januvia (Sitagliptin) was the first DPP-4 inhibitor drug which worked by increasing levels of GLP-1 in the bloodstream, and Galvus (Vildagliptin) and Nesina (Alogliptin) came soon after. Onglyza (Saxagliptin), Kombiglyze (Saxagliptin mixed with metformin), and Tradjenta (Linagliptin) are the newest drugs in this family. The gliptin drugs are typically used for patients who have not responded to sulphonylureas or metformin.
Onglyza (Saxagliptin) Multidistrict Litigation
In February of this year the United States Judicial Panel on Multidistrict Litigation established an Onglyza (Saxagliptin) Multidistrict Litigation in the Eastern District of Kentucky. There are at least 84 Onglyza and Kombiglyze lawsuits in this MDL; all share numerous factual questions, in that the use of one of these drugs caused them to develop heart failure or other conditions such as cardiovascular injury, myocardial infarction or congestive heart failure.
AstraZeneca and Bristol-Myers Squibb opposed the MDL, arguing the allegations by the plaintiffs are supported by only one study (SAVOR), which supports only claims of heart failure, not claims of other injuries, such as coronary artery disease, acute hypoxic respiratory failure and congestive heart failure. The drug manufacturer’s objections were found insufficient to overcome the advantages that the centralization of an Onglyza (Saxagliptin) multidistrict litigation will bring.
Onglyza (Saxagliptin) Injury Lawsuit
When Onglyza was first marketed in 2009, it was considered safe, however there is increasing evidence that some of the risks associated with Onglyza can be fatal. Because of this, more and more patients who have suffered harm from the drug are speaking with an Onglyza (Saxagliptin) attorney who can help them decide whether they have a valid Onglyza (Saxagliptin) lawsuit. Patients who are filing Onglyza (Saxagliptin) injury lawsuits allege the company did not market the drug in a safe manner, that the company knew about the dangers of the drug, but failed to warn the public, and that the company manufactured a dangerous drug.
Onglyza (Saxagliptin) Wrongful Death Lawsuit
While there have been no confirmed deaths associated with Onglyza, the potentially serious side effects of the drug could lead to death, particularly among those who have suffered Onglyza (Saxagliptin) pancreatitis, Onglyza (Saxagliptin) pancreatic cancer, Onglyza (Saxagliptin) heart failure or Onglyza (Saxagliptin) thyroid cancer. In 2015, the FDA determined, based on the findings of a clinical trial on the heart effects of Onglyza, that the drug was associated with
“significant or near-significant increased risk of death from all causes, not just heart problems.” The cause of the increased risk of death was not included in the FDA analysis. If a loved one has died from complications related to Onglyza, you could potentially file an Onglyza (Saxagliptin) wrongful death lawsuit.
Onglyza (Saxagliptin) Heart Failure Lawsuit
In 2016, the FDA called for stronger heart-failure warnings on the label of Onglyza—soon after, AstraZeneca and Bristol-Myers Squibb were hit with at least 14 Onglyza (Saxagliptin) heart failure lawsuits. These lawsuits, filed in the District of New Jersey, assert the drug manufacturers of Onglyza failed to warn users that Onglyza—as well as a related product, Kombiglyza XR, which contains Saxagliptin and metformin—can cause congestive heart failure, cardiac arrest, and even death related to heart failure.
Plaintiffs in these Onglyza (Saxagliptin) heart failure lawsuits also claim the manufacturers marketed Onglyza prior to conducting clinical trials to determine whether cardiac risks among those taking the drug were increased. In fact, the FDA stated that patients taking Onglyza had a 27 percent increased risk of hospitalization for heart failure compared to those taking a placebo.
Onglyza (Saxagliptin) Pancreatic Cancer Lawsuit
Because Onglyza has been found to increase the risk of pancreatitis, it is likely the drug also increases the risk of pancreatic cancer (since pancreatitis is often a precursor to pancreatic cancer). In fact, Onglyza has been associated with a heightened risk of pancreatitis, pancreatic cancer and thyroid cancer. Onglyza (Saxagliptin) pancreatic cancer is widely considered to be perhaps the most dangerous side effect of Onglyza and other DPP-4 drugs like it.
Onglyza (Saxagliptin) pancreatic cancer is not usually diagnosed until it has reached later, more dangerous stages where it is much more difficult to treat and has a higher fatality rate. An incretin mimetic study found that those with Type 2 diabetes who took Onglyza or another DPP-4 drug had pancreases which were 40 percent larger than normal. The same study showed patients taking Onglyza or a similar drug had tumors within the pancreas as well as precancerous cell growth in the pancreas.
Onglyza (Saxagliptin) Thyroid Cancer Lawsuit
Onglyza has also been linked to an increased risk of thyroid cancer—a number of studies and multiple adverse event reports filed with the U.S. Food and Drug Administration have linked the drug to a heightened risk of thyroid cancer. Since thyroid cancer is a slower-growing cancer which can take many years to develop, it is hard to determine whether thyroid cancer is a direct side effect of Onglyza. That being said, the FDA has received dozens of reports of thyroid cancer among patients taking this type of drug. Additional studies are currently being done to determine whether thyroid cancer is a side effect of Onglyza.
Onglyza (Saxagliptin) Lawsuit Attorneys
Patients and family members who have suffered Onglyza (Saxagliptin) injuries could be entitled to compensation in the form of medical expenses, pain and suffering, lost wages, and possibly even punitive damages, or wrongful death expenses in the case of an Onglyza death. An Onglyza (Saxagliptin) attorney from Sullo & Sullo can evaluate your medical injuries and issues associated with the drug. It could be beneficial for you to speak to a Sullo & Sullo attorney as soon as possible.